Valneva tops SBF 120 on long-term efficacy of IXCHIQ vaccine

Valneva SE

30/09/2025 10:35

** Valneva VLS.PA shares soar 11% after the French vaccine maker reported long-term efficacy of IXCHIQ vaccine for chikungunya

** Valneva announced a 95% seroresponse four years post-IXCHIQ vaccination

** The results confirm long-lasting antibody persistence across all age groups investigated, the company said

** " It's showing quite robust long-term efficacy," an analyst at Rx securities says

** "11% looks a bit aggressive in terms of the mood, but it's obviously good news on that vaccine," analyst adds

** Including today's rise the stock has gained 134.74 % YTD

** The stock trades at the top of France's SBF 120 Index .SBF120

 (Reporting by Michal Aleksandrowicz and Hugo Lhomedet)

 ((michal.aleksandrowicz@tr.com))